West Cancer Center

LUNG: EGFR mutation; "Checkmate 370"

A master protocol of Phase 1/2 studies of nivolumab in advanced NSCLC using nivolumab as maintenance after induction chemotherapy or as first-line treatment alone or in combination with standard of care therapies

Title

Bristol-Myers Squibb CA209-370

Study Title

Site Link

NCT02574078

Malignancy

Lung, Metastatic Lung Cancer, NSCLC, squamous cell lung cancer, lung adenocarcinoma, non-small cell lung cancer

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

1st line

Investigational Agent

Nivolumab

Drug Class

PD-1 inhibitor

Jason Chandler, MD

Sponsor

Bristol-Myers Squibb

Phase

Phase 2

Status

Closed to Accrual

Key Eligibility Criteria

NCT02574078

Key Eligibility Criteria Details

Locally advanced or metastatic NSCLC
For currently open cohort must have EGFR mutation
ECOG PS 0-2
Tumor tissue available for biomarker evaluation
No active CNS involvement
No known or active autoimmune disease
No known HIV, HBV, HCV

Objective

Primary- PFS and OS: Secondary- DoR, ORR

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

NSCLC, EGFR mutation

Dosing Frequency

Control Agents

standard therapy or targeted therapy

Study Protocol

Randomized

Yes